Why I’m Looking to Add Exposure After the Nasdaq’s Worst Day Since June
Thursday’s selloff isn’t a signal to cut exposure. It is a signal to look where the money is going.
AI Names Crater, Average Stocks Rise in Dramatic Rotation
The gap is closing, but the opportunity is in new leaders, not broken AI names.
Market Gap Narrows and It’s Time to Put Cash to Work
The AI complex is getting hit on earnings while small caps, biotech, retail and defensive pharma hold up. Here’s what I’m buying.
Key Earnings See Negative Reactions as Rotation Hits a Bump in the Road
SpaceX spent more, Tesla spent less, and Meta proved its spending works. The market is selling all three.
Good News for Tesla and Meta, But Good Enough to Attract New Buyers?
Mark Zuckerberg said his company hit major milestones toward what he calls personal super intelligence.
I’m Bottom Fishing This Data Center Play the Right Way
SpaceX has confirmed the strong need for data centers with power supplies.
SpaceX (SPCX): Post-Q3 Target Raises, October 21
The SpaceX ($SPCX) quarter beat on revenue and EBITDA across all three segments (Intelligence/AI, Space, Connectivity). The only blemish was a miss on Starlink subscriber adds, offset by better pricing. Guidance calls for revenue of $33B to $37B by Q1 FY27. Management says it expects 2 to 3 GW of compute by year-end 2026 and plans to add 10 GW in 2027, well above prior expectations, and told JPMorgan it is not considering raising equity.
Price targets:
- JPMorgan: $500 from $240 (Overweight). Biggest move. Says the forward driver is superintelligence, not the segment beats.
- Cantor Fitzgerald: $345 from $246 (Overweight). Sees $500B to $1T in year-end 2027 ARR, self-funded compute expansion, and chip supply constraints giving SpaceX pricing power.
- Barclays: $300 from $254 (Overweight). Model update on the beat.
- Morgan Stanley: $300 reiterated (Overweight). Says the story is only now getting interesting.
- Citi: $240 from $200 (Buy). Also opened a 90-day upside catalyst watch, pointing to Q4 beat-and-raise continuation and Starship Flight 15 as a major reusability catalyst.
- UBS: $230 from $210 (Buy). New compute deals ramping in Q4, Starship catch milestones, Grok improvements.
- TD Cowen: $224 from $200 (Buy). Estimates up on the beat.
- Susquehanna: $176 from $173 (Neutral). The lone holdout. Flags execution risk on the compute buildout and dependence on Starship commercialization.
SpaceX Beats, but the Test Is Whether It Can Build on the Gains
Last quarter’s strong AI beats faded. Will it be different this time? Here’s my plan for SPCX.
Gap Between Market’s 2 Tiers Starts to Close
SpaceX saw beats on both the top and bottom line but is trading flat in front of the conference call.
How I’m Trading SpaceX Earnings as Rotation Gains Traction
Money is moving out of tech ahead of the big reports, and Oscar Health just gave me a reason to add.